Plasma Fractionation Market Size to Hit USD 73.48 Billion by 2033

Plasma Fractionation Market Size, Share, and Growth By Product Type (Immunoglobulins, Albumin, Blood Coagulation Factors, Alpha-1 Antitrypsin, Other Plasma Protein Products), By Therapeutic Area (Primary Immunodeficiency Disorders, Hemophilia and Bleeding Disorders, Alpha-1 Antitrypsin Deficiency, Neurological Disorders, Autoimmune Diseases, Infectious Diseases, Other Therapeutic Areas), By End-User (Hospitals, Specialty Clinics, Home Healthcare Settings), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Market Forecast, 2026 – 2033

  • Published: Feb, 2026
  • Report ID: 553
  • Pages: 160+
  • Format: PDF / Excel.

This report contains the Latest Market Figures, Statistics, and Data.

Get a Sample
logo

Plasma Fractionation Market Size to Hit USD 73.48 Billion by 2033

(An Updated Version is Available)

1. Executive Summary

  • 1.1 Market Overview and Definition

  • 1.2 Key Market Highlights and Findings

  • 1.3 Market Size and Growth Projections (2025–2033)

  • 1.4 Market Segmentation Snapshot

  • 1.5 Regional Market Snapshot

  • 1.6 Competitive Landscape Overview

  • 1.7 Key Growth Drivers and Strategic Insights

2. Research Methodology

  • 2.1 Research Framework and Approach

  • 2.2 Data Collection Methods

    • 2.2.1 Primary Research (Expert Interviews, Industry Surveys, C‑Suite Consultation)

    • 2.2.2 Secondary Research (Industry Reports, Trade Publications, Company Filings)

  • 2.3 Market Size Estimation Methodology

    • 2.3.1 Top‑Down Approach

    • 2.3.2 Bottom‑Up Approach

  • 2.4 Data Triangulation and Validation Process

  • 2.5 Forecasting Models and Techniques

  • 2.6 Research Assumptions and Limitations

  • 2.7 Base Year (2025), Current Year (2026), and Forecast Period (2026–2033)

3. Market Introduction

  • 3.1 Market Definition and Scope

  • 3.2 Overview of Plasma Fractionation and Plasma‑Derived Therapies

  • 3.3 Types of Plasma‑Derived Products and Their Applications

  • 3.4 Market Taxonomy and Segmentation Framework

  • 3.5 Key Market Indicators

  • 3.6 Currency and Units Considered

  • 3.7 Stakeholder Ecosystem

4. Plasma Fractionation Market Characteristics

  • 4.1 Product Overview and Technical Specifications

  • 4.2 Plasma Collection and Processing Technologies

  • 4.3 Fractionation Methods (Centrifugation, Depth Filtration, Chromatography)

  • 4.4 Regulatory Classifications and Standards

  • 4.5 Comparison: Immunoglobulins, Coagulation Factors, Albumin, and Other Plasma Proteins

5. Assumptions and Acronyms Used

  • 5.1 List of Key Assumptions

  • 5.2 Currency and Pricing Considerations

  • 5.3 Acronyms and Abbreviations

6. Market Dynamics

  • 6.1 Introduction

  • 6.2 Market Drivers

    • 6.2.1 Rising Prevalence of Chronic and Rare Diseases (Hemophilia, Immunodeficiencies, Liver Disease)

    • 6.2.2 Increasing Demand for Plasma‑Derived Therapies (Immunoglobulins, Coagulation Factors, Albumin)

    • 6.2.3 Advancements in Fractionation Technologies (Centrifugation, Chromatography)

    • 6.2.4 Expansion of Plasma Collection Centers and Donor Pool

    • 6.2.5 Supportive Government Policies and Healthcare Investments

  • 6.3 Market Restraints

    • 6.3.1 Limited Plasma Availability and Donor Shortages

    • 6.3.2 High Cost of Plasma Collection, Processing, and Fractionation

    • 6.3.3 Stringent Regulatory and Safety Requirements

    • 6.3.4 Competition from Recombinant and Alternative Therapies

  • 6.4 Market Opportunities

    • 6.4.1 Development of Novel Plasma‑Derived Therapies and Biologics

    • 6.4.2 Expansion in Emerging Markets (Asia‑Pacific, Latin America)

    • 6.4.3 Growth of Immunoglobulin and Coagulation Factor Segments

    • 6.4.4 Integration with Digital Health and Supply Chain Optimization

  • 6.5 Market Challenges

    • 6.5.1 Ensuring Plasma Safety and Quality Control

    • 6.5.2 Managing Supply Chain and Raw Material Costs

    • 6.5.3 Balancing Innovation, Cost, and Accessibility

    • 6.5.4 Addressing Ethical and Donor‑Related Issues

  • 6.6 Market Trends

    • 6.6.1 Shift Toward Chromatography‑Based Fractionation for Higher Purity

    • 6.6.2 Growth of Immunoglobulin and Coagulation Factor Therapies

    • 6.6.3 Integration with Sustainable and Green Manufacturing Practices

    • 6.6.4 Focus on Plasma‑Derived Therapies for Rare and Orphan Diseases

    • 6.6.5 Rise of Retail Pharmacy and Direct‑to‑Consumer Distribution

7. Value Chain and Ecosystem Analysis

  • 7.1 Overview of Plasma Fractionation Value Chain

  • 7.2 Plasma Donors and Collection Centers

  • 7.3 Plasma Processing and Fractionation Facilities

  • 7.4 Pharmaceutical and Biotech Manufacturers

  • 7.5 Distributors and Medical Supply Wholesalers

  • 7.6 End‑User Channels (Hospitals, Clinics, Retail Pharmacies)

  • 7.7 Regulatory and Certification Bodies

  • 7.8 After‑Sales Services and Patient Support Programs

  • 7.9 Value Addition at Each Stage

8. Porter's Five Forces Analysis

  • 8.1 Threat of New Entrants

  • 8.2 Bargaining Power of Suppliers (Plasma Donors, Technology Providers)

  • 8.3 Bargaining Power of Buyers (Hospitals, GPOs, Patients)

  • 8.4 Threat of Substitute Products and Technologies

  • 8.5 Intensity of Competitive Rivalry

9. PESTEL Analysis

  • 9.1 Political Factors (Government Healthcare Policies, Reimbursement, Trade Regulations)

  • 9.2 Economic Factors (Healthcare Spending, Plasma‑Derived Therapy Costs, Economic Development)

  • 9.3 Social Factors (Aging Population, Chronic Disease Awareness, Donor Participation)

  • 9.4 Technological Factors (Fractionation Technologies, Chromatography, Digital Health)

  • 9.5 Environmental Factors (Sustainability, Waste Management, Energy Efficiency)

  • 9.6 Legal and Regulatory Factors (FDA, EMA, WHO Guidelines, Product Safety)

10. Market Attractiveness Analysis

  • 10.1 By Product Type (Immunoglobulins, Coagulation Factors, Albumin, Alpha‑1‑Antitrypsin, Others)

  • 10.2 By Method (Centrifugation, Depth Filtration, Chromatography)

  • 10.3 By Application (Primary Immunodeficiency, Hemophilia, Liver Disease, Autoimmune Disorders, Others)

  • 10.4 By End User (Hospitals, Clinics, Retail Pharmacies, Home Healthcare, Others)

  • 10.5 By Distribution Channel (Direct Sales, Medical Distributors, Online Retailers)

  • 10.6 By Region

11. COVID‑19 Impact Analysis

  • 11.1 Introduction and Overview

  • 11.2 Impact During the Pandemic

  • 11.3 Changes in Plasma Collection and Fractionation Demand

  • 11.4 Post‑Pandemic Recovery and Market Normalization

12. Impact of Advanced Fractionation Technologies on Plasma Fractionation Market

  • 12.1 Introduction to Advanced Fractionation Methods

  • 12.2 Centrifugation‑Based Fractionation and Its Advantages

  • 12.3 Depth Filtration for Plasma Clarification

  • 12.4 Chromatography for High‑Purity Protein Isolation

  • 12.5 Integration with Digital Health and Supply Chain Optimization

  • 12.6 Future Technology‑Driven Market Opportunities

13. Global Plasma Fractionation Market Size and Forecast (2025–2033)

  • 13.1 Historical Market Size and Trends (2021–2024)

  • 13.2 Base Year Market Size (2025)

  • 13.3 Current Year Market Size (2026)

  • 13.4 Market Size Forecast (USD Billion, 2026–2033)

  • 13.5 Year‑on‑Year Growth Analysis

  • 13.6 CAGR Analysis (2026–2033)

  • 13.7 Absolute Dollar Opportunity Assessment

14. Market Segmentation Analysis

14.1 By Product Type

  • 14.1.1 Immunoglobulins

    • Intravenous Immunoglobulin (IVIG)

    • Subcutaneous Immunoglobulin (SCIG)

  • 14.1.2 Coagulation Factors

    • Factor VIII

    • Factor IX

    • Von Willebrand Factor

  • 14.1.3 Albumin

  • 14.1.4 Alpha‑1‑Antitrypsin

  • 14.1.5 Others (Prothrombin Complex, Fibrinogen, Antithrombin)

14.2 By Method

  • 14.2.1 Centrifugation

  • 14.2.2 Depth Filtration

  • 14.2.3 Chromatography

14.3 By Application

  • 14.3.1 Primary Immunodeficiency

  • 14.3.2 Hemophilia and Bleeding Disorders

  • 14.3.3 Liver Disease and Cirrhosis

  • 14.3.4 Autoimmune and Inflammatory Disorders

  • 14.3.5 Neurological Disorders

  • 14.3.6 Others (Burns, Shock, Trauma)

14.4 By End User

  • 14.4.1 Hospitals

  • 14.4.2 Clinics

  • 14.4.3 Retail Pharmacies

  • 14.4.4 Home Healthcare

  • 14.4.5 Others

14.5 By Distribution Channel

  • 14.5.1 Direct Sales to Institutions

  • 14.5.2 Medical Distributors and Wholesalers

  • 14.5.3 Online Retailers and E‑Commerce

14.6 By Region

  • 14.6.1 North America

  • 14.6.2 Europe

  • 14.6.3 Asia Pacific

  • 14.6.4 Latin America

  • 14.6.5 Middle East and Africa

15. Regional Market Analysis

15.1 North America

  • 15.1.1 Market Overview and Key Trends

  • 15.1.2 Market Size and Forecast (2025–2033)

  • 15.1.3 Market Share by Segment

  • 15.1.4 Country‑Level Analysis

    • United States

    • Canada

    • Mexico

  • 15.1.5 Market Attractiveness Analysis

15.2 Europe

  • 15.2.1 Market Overview and Key Trends

  • 15.2.2 Market Size and Forecast (2025–2033)

  • 15.2.3 Market Share by Segment

  • 15.2.4 Country‑Level Analysis

    • Germany

    • United Kingdom

    • France

    • Italy

    • Spain

    • Nordics (Denmark, Norway, Sweden)

    • Rest of Europe

  • 15.2.5 Market Attractiveness Analysis

15.3 Asia Pacific

  • 15.3.1 Market Overview and Key Trends

  • 15.3.2 Market Size and Forecast (2025–2033)

  • 15.3.3 Market Share by Segment

  • 15.3.4 Country‑Level Analysis

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Thailand

    • ASEAN

    • Rest of Asia Pacific

  • 15.3.5 Market Attractiveness Analysis

15.4 Latin America

  • 15.4.1 Market Overview and Key Trends

  • 15.4.2 Market Size and Forecast (2025–2033)

  • 15.4.3 Market Share by Segment

  • 15.4.4 Country‑Level Analysis

    • Brazil

    • Mexico

    • Argentina

    • Rest of Latin America

  • 15.4.5 Market Attractiveness Analysis

15.5 Middle East and Africa

  • 15.5.1 Market Overview and Key Trends

  • 15.5.2 Market Size and Forecast (2025–2033)

  • 15.5.3 Market Share by Segment

  • 15.5.4 Country‑Level Analysis

    • GCC Countries (UAE, Saudi Arabia, Qatar, Kuwait)

    • South Africa

    • Egypt

    • Rest of MEA

  • 15.5.5 Market Attractiveness Analysis

16. Competitive Landscape

  • 16.1 Market Concentration and Competitive Intensity

  • 16.2 Market Share Analysis of Key Players (2024/2025)

  • 16.3 Market Ranking and Positioning Analysis

  • 16.4 Competitive Strategies and Benchmarking

  • 16.5 Recent Developments and Strategic Moves

    • 16.5.1 Product Launches and Innovations

    • 16.5.2 Mergers and Acquisitions

    • 16.5.3 Partnerships and Collaborations

    • 16.5.4 Regulatory Approvals and Certifications

    • 16.5.5 Geographic Expansion and Market Entry

  • 16.6 Competitive Dashboard and Company Evaluation Matrix

17. Company Profiles

The final report includes a complete list of companies

17.1 CSL Limited (CSL Behring)

  • Company Overview

  • Financial Performance

  • Product Portfolio

  • Strategic Initiatives

  • SWOT Analysis

17.2 Grifols S.A.

17.3 Octapharma AG

17.4 Takeda Pharmaceutical Company Limited

17.5 Kedrion S.p.A.

17.6 Biotest AG

17.7 LFB Group

17.8 ProMetic Life Sciences Inc.

17.9 Cangene Corporation (Emergent BioSolutions)

17.10 ADMA Biologics, Inc.

17.11 BPL Group Ltd.

17.12 NantKwest, Inc.

17.13 ZLB Behring (Baxter International Inc.)

17.14 Alpha Therapeutic Corporation (Takeda)

17.15 Shanghai RAAS Blood Products Co., Ltd.

18. Technology and Innovation Trends

  • 18.1 Advancements in Chromatography and High‑Purity Fractionation

  • 18.2 Development of Novel Plasma‑Derived Therapies and Biologics

  • 18.3 Integration with Digital Health and Supply Chain Optimization

  • 18.4 Focus on Sustainable and Green Manufacturing Practices

  • 18.5 Expansion of Immunoglobulin and Coagulation Factor Therapies

19. Regulatory and Compliance Landscape

  • 19.1 Overview of Global Regulatory Framework

  • 19.2 FDA Regulations and 510(k) Clearance Process (U.S.)

  • 19.3 European Medicines Agency (EMA) Regulations

  • 19.4 WHO Guidelines for Plasma‑Derived Therapies

  • 19.5 Regional Certification and Approval Processes

  • 19.6 Impact of Regulations on Market Adoption

20. Patent and Intellectual Property Analysis

  • 20.1 Key Patents and Innovations in Plasma Fractionation

  • 20.2 Patent Landscape by Product Type and Method

  • 20.3 Regional Patent Filing Trends

  • 20.4 Leading Companies in Patent Holdings

  • 20.5 Emerging IP Opportunities and White Spaces

21. ESG and Sustainability Analysis

  • 21.1 Environmental Impact and Sustainable Manufacturing

  • 21.2 Social Responsibility and Access to Plasma‑Derived Therapies

  • 21.3 Governance and Compliance Standards

  • 21.4 Corporate ESG Initiatives by Leading Players

22. Use Case and Application Analysis

  • 22.1 Hospitals: Treatment of Chronic and Rare Diseases

  • 22.2 Clinics: Outpatient Plasma Therapy Administration

  • 22.3 Retail Pharmacies: Direct‑to‑Consumer Distribution

  • 22.4 Home Healthcare: Home‑Based Infusion Therapy

  • 22.5 Research Institutes: Clinical Trials and Innovation

23. Commercial Use Cases Across Industries

  • 23.1 Healthcare Facilities: Plasma‑Derived Therapy Administration

  • 23.2 Pharmaceutical and Biotech Companies: Plasma Fractionation and Manufacturing

  • 23.3 E‑Commerce Platforms: Online Distribution and Medical Supply

  • 23.4 Group Purchasing Organizations (GPOs): Bulk Procurement and Cost Optimization

  • 23.5 Research Institutes: Plasma‑Derived Therapy Innovation

24. Consumer and End‑User Analysis

  • 24.1 Purchase Decision Factors and Criteria

  • 24.2 Total Cost of Ownership and Affordability Analysis

  • 24.3 Technology Adoption Patterns and Maturity Levels

  • 24.4 Customer Pain Points and Service Expectations

  • 24.5 Impact of Donor Participation and Plasma Availability

25. Plasma Fractionation Market Trends and Strategies

  • 25.1 Current Market Trends

    • 25.1.1 Shift Toward Chromatography‑Based Fractionation

    • 25.1.2 Growth of Immunoglobulin and Coagulation Factor Segments

    • 25.1.3 Integration with Digital Health and Supply Chain Optimization

  • 25.2 Market Entry and Expansion Strategies

  • 25.3 Product Innovation and Differentiation Strategies

  • 25.4 Pricing and Cost Optimization Strategies

  • 25.5 Partnership and Collaboration Strategies

26. Strategic Recommendations

  • 26.1 Recommendations for Market Leaders

  • 26.2 Recommendations for New Entrants and Startups

  • 26.3 Recommendations for Investors and Venture Capital

  • 26.4 Regional Expansion and Market Penetration Strategies

  • 26.5 Product Innovation and Differentiation Strategies

  • 26.6 Partnership and Ecosystem Development Opportunities

27. Key Mergers and Acquisitions

  • 27.1 Overview of M&A Activity in Plasma Fractionation Market

  • 27.2 Major Transactions and Strategic Rationale

  • 27.3 Impact on Market Dynamics

28. High Potential Segments and Growth Strategies

  • 28.1 High‑Growth Segments and Regions

  • 28.2 Segments Offering Most New Opportunities

  • 28.3 Growth Strategies

    • 28.3.1 Market Trend‑Based Strategies

    • 28.3.2 Competitor Strategies

29. Future Market Outlook and Trends (2026–2033)

  • 29.1 Evolution of Advanced Fractionation Technologies

  • 29.2 Integration with Digital Health and Supply Chain Optimization

  • 29.3 Rise of Plasma‑Derived Therapies for Rare and Orphan Diseases

  • 29.4 Expansion of Plasma Fractionation Market in Emerging Healthcare Markets

30. Conclusion

  • 30.1 Summary of Key Findings

  • 30.2 Market Outlook (2025–2033)

  • 30.3 Future Growth Drivers and Opportunities

  • 30.4 Final Insights and Strategic Perspectives

31. Appendix

  • 31.1 List of Abbreviations and Acronyms

  • 31.2 Glossary of Technical Terms

  • 31.3 Research Instruments and Questionnaires (Sample)

  • 31.4 List of Figures and Tables

  • 31.5 List of Primary and Secondary Data Sources

  • 31.6 Additional Resources and References

32. Disclaimer

Enhance your decision-making capabilities with a 5 Reports-in-1
Bundle deal for - more than 40% off!

Our professional analysts will provide you with immediate assistance.